Relationship between articular and nonarticular manifestations in inflammatory bowel diseases

Fatemi, Alimohammad; Jazi, Hourossadat Hashemi; Emami, Mohammad Hasan; Kazemizadeh, Amir; Tavakkoli, Hamid; Smiley, Abbas

doi:10.4103/1735-1995.183989

Cited by 9 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, the overall prevalence of lower back pain in patients with UC was 30% compared to 23% in the control group. In addition to lower back pain, one study reported that pain in the ankle and the knee was common in patients with IBD which is in line with the findings in our study [28]. Moreover, the SpAs can affect the axial skeleton as well as the peripheral joints, causing MSK pain in virtually all parts of the body [5,29,30].…”

Section: Discussionsupporting

confidence: 91%

Increased chronic pain in patients with ulcerative colitis is mostly associated to increased disease activity. A cross-sectional case-control study

Pettersson

Kragsbjerg

Hamrin

et al. 2020

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

Backgrounds/aims: Musculoskeletal symptoms are common in patients with ulcerative colitis (UC), but no study has compared the prevalence of chronic pain to controls from a general population. Methods: Patients with UC (n ¼ 1164) and controls (n ¼ 3867) were sent questionnaires comprising demography, history of pain, pain localization and UC patients' Patient-Simple Clinical Colitis Activity Index. Chronic regional pain (ChRP) and chronic widespread pain (ChWP) were defined as having pain for at least 3 months. Results: The response rate for the patients with UC was 49.0% and for the control persons 61.7% (p < .001). The reported prevalence of ChRP and ChWP was higher in patients with UC versus controls (33.1% vs. 24.2%; p < .001 and 19.8% vs. 12.5%; p < .001). The patients with UC reported significantly more pain in the regions 'lower back', 'hip/upper leg' and 'lower leg/foot' compared to controls. The patients with P-SCCAI 5 (n ¼ 121) reported more ChWP than patients with P-SCCAI <5 (n ¼ 426) (46.3% vs. 12.7%; p < .001) and controls (n ¼ 2425) (46.3 vs. 12.5%; p < .001) in all body regions. No significant difference in ChWP was found between patients with P-SCCAI <5 and controls (12.7% vs. 12.5%; p ¼ .917). Conclusions: Patients with UC reported more chronic pain than controls from the general population, especially from the lower back and hip region. Higher UC disease activity was associated with more pain in all body regions.

show abstract

Section: Discussionsupporting

confidence: 91%

Increased chronic pain in patients with ulcerative colitis is mostly associated to increased disease activity. A cross-sectional case-control study

Pettersson

Kragsbjerg

Hamrin

et al. 2020

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

“…The overall prevalence of rheumatic manifestations was 13%. The data published in this aspect vary depending on the country in which the work was carried out and the methodology used, varying between 4.4 and 28% [24][25][26][27][28][29][30]. Some series have even published that the prevalence of peripheral arthritis may reach up to 40%, although these series controversially include arthralgias in this category of EIM [3].…”

Section: Discussionmentioning

confidence: 99%

Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry

et al. 2020

View full text Add to dashboard Cite

Background Patients with inflammatory bowel disease (IBD) may present extraintestinal manifestations (EIMs) that affect the joints, skin, eyes, and hepatobiliary area, among others. Aims Our aim was to analyse the prevalence and characteristics of EIMs in patients with IBD and to identify the possible risk factors associated with the development of EIMs in the largest series published to date. Methods Observational, cross-sectional study including patients from the Spanish ENEIDA registry promoted by GETECCU. We retrospectively identified all cases of EIMs in the ENEIDA registry until January 2018. ResultsThe study included 31,077 patients, 5779 of whom had at least one EIM (global prevalence 19%; 95% CI 18.2-19.0). Among the different types of EIMs, rheumatic manifestations had a prevalence of 13% (95% CI 12.9-13.7; 63% of EIMs), with a prevalence of 5% (95% CI 4.7-5.2) for mucocutaneous manifestations, 2.1% (95% CI 1.9-2.2) for ocular manifestations, and 0.7% (95% CI 0.6-0.8) for hepatobiliary manifestations. The multivariable analysis showed that the type of IBD (Crohn's disease, p < 0.001), gender (female, p < 0.001), the need for an immunomodulator (p < 0.001) or biologic drugs (p < 0.001), a previous family history of IBD (p < 0.001), and an extensive location of IBD (p < 0.001) were risk factors for the presence of EIMs. Conclusions One-fifth of patients with IBD may have associated EIMs, with rheumatic manifestations as the most frequent (> 60% of EIMs). Female patients with severe Crohn's disease represent the group with the highest risk of developing EIMs. These patients should therefore be specially monitored and referred to the corresponding specialist when suggestive symptoms appear.

show abstract

“…The FMS frequency was reported similar to the general population. FMS frequency was reported to be 2.1% in CD and 1.1% in UC in the Iranian population, similar to the normal population (20). In these two studies, although FMS was more frequent in CD, there was no increase in the group of IBD according to the normal population.…”

Section: Discussionmentioning

confidence: 51%

Does the fibromyalgia affect the quality of life in the patients with inflammatory bowel disease

Dilekçi

Can

Gürler

et al. 2021

Journal of Health Sciences and Medicine

View full text Add to dashboard Cite

Aim: Data on soft tissue rheumatism, especially fibromyalgia syndrome is limited in inflammatory bowel disease. Our aim in our study is to determine the prevalence of fibromyalgia syndrome and to evaluate the impact on quality of life in inflammatory bowel disease. Material and Method: 60 ulcerative colitis and 34 Crohn's disease patients were included. 2010/2011 and 2016 American College of Rheumatology criteria were used for fibromyalgia syndrome diagnosis. A Fibromyalgia impact survey was applied to all patients. Results: According to the American College of Rheumatology-2010/2011 criteria, fibromyalgia syndrome frequencies were determined as 29.8% in inflammatory bowel disease, 23.4% in Crohn's disease, and 33.3% in ulcerative colitis (P>0.05). The frequency of fibromyalgia syndrome was significantly higher in inflammatory bowel disease and especially more in females. There was no significant difference between ulcerative colitis and Crohn's disease in terms of widespread-pain-index, somaticsymptom-severity, and fibromyalgia syndrome scores. Fibromyalgia impact scores were found significantly higher in those with fibromyalgia syndrome in inflammatory bowel disease, ulcerative colitis, and Crohn's disease. Conclusions: This is the first study to show the frequency of fibromyalgia syndrome in patients with inflammatory bowel disease in the Turkish population. Fibromyalgia syndrome is increased in inflammatory bowel disease patients and more in ulcerative colitis and female. The quality of life is more affected in inflammatory bowel disease patients with fibromyalgia syndrome.

show abstract

Relationship between articular and nonarticular manifestations in inflammatory bowel diseases

Cited by 9 publications

References 26 publications

Increased chronic pain in patients with ulcerative colitis is mostly associated to increased disease activity. A cross-sectional case-control study

Increased chronic pain in patients with ulcerative colitis is mostly associated to increased disease activity. A cross-sectional case-control study

Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry

Does the fibromyalgia affect the quality of life in the patients with inflammatory bowel disease

Contact Info

Product

Resources

About